Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomohisa Nakada

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Drug Metabolism and Pharmacokinetics|May 26, 2024
Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trialsRyuta Saito, Tomohisa Nakada
British Journal of Pharmacology|March 31, 2022
Systems model identifies baseline cytokine concentrations as potential predictors of rheumatoid arthritis inflammatory response to biologicsTomohisa Nakada, Donald E Mager
CPT: Pharmacometrics & Systems Pharmacology|November 25, 2025
B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab-Mediated B Cell Depletion in Rheumatic DiseasesTomohisa Nakada, Donald E Mager
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 2023
Quantitative Consideration of Clinical Increases in Serum Creatinine Caused by Renal Transporter InhibitionTomohisa Nakada, Toshiyuki Kudo, Kiyomi Ito
Drug Metabolism and Pharmacokinetics|January 24, 2018
Quantitative analysis of elevation of serum creatinine via renal transporter inhibition by trimethoprim in healthy subjects using physiologically-based pharmacokinetic modelTomohisa Nakada, Toshiyuki Kudo, Toshiyuki Kume, et al.
Drug Metabolism and Pharmacokinetics|June 10, 2019
Estimation of changes in serum creatinine and creatinine clearance caused by renal transporter inhibition in healthy subjectsTomohisa Nakada, Toshiyuki Kudo, Toshiyuki Kume, et al.
Biopharmaceutics & Drug Disposition|October 21, 2020
Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamicsKazumi Mori-Anai, Yoshihiko Tashima, Tomohisa Nakada, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 14, 2018
Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in AnimalsHidetoshi Shimizu, Kosuke Yoshida, Tomohisa Nakada, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 5, 2017
Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using StatinsTakashi Yoshikado, Kota Toshimoto, Tomohisa Nakada, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 23, 2026
Integrating B Cell Differentiation Model With Real-World Data Informs Determinants for Antibody-Secreting Cell Depletions in Systemic SclerosisTomohisa Nakada, Ryuta Saito, Sho Ishigaki, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Drug Metabolism and Pharmacokinetics|May 26, 2024
Insights into drug development with quantitative systems pharmacology: A prospective case study of uncovering hyperkalemia risk in diabetic nephropathy with virtual clinical trialsRyuta Saito, Tomohisa Nakada
British Journal of Pharmacology|March 31, 2022
Systems model identifies baseline cytokine concentrations as potential predictors of rheumatoid arthritis inflammatory response to biologicsTomohisa Nakada, Donald E Mager
CPT: Pharmacometrics & Systems Pharmacology|November 25, 2025
B Cell Differentiation Model for Identifying Predictors of Responses to Rituximab-Mediated B Cell Depletion in Rheumatic DiseasesTomohisa Nakada, Donald E Mager
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 1, 2023
Quantitative Consideration of Clinical Increases in Serum Creatinine Caused by Renal Transporter InhibitionTomohisa Nakada, Toshiyuki Kudo, Kiyomi Ito
Drug Metabolism and Pharmacokinetics|January 24, 2018
Quantitative analysis of elevation of serum creatinine via renal transporter inhibition by trimethoprim in healthy subjects using physiologically-based pharmacokinetic modelTomohisa Nakada, Toshiyuki Kudo, Toshiyuki Kume, et al.
Drug Metabolism and Pharmacokinetics|June 10, 2019
Estimation of changes in serum creatinine and creatinine clearance caused by renal transporter inhibition in healthy subjectsTomohisa Nakada, Toshiyuki Kudo, Toshiyuki Kume, et al.
Biopharmaceutics & Drug Disposition|October 21, 2020
Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamicsKazumi Mori-Anai, Yoshihiko Tashima, Tomohisa Nakada, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 14, 2018
Prediction of Human Distribution Volumes of Compounds in Various Elimination Phases Using Physiologically Based Pharmacokinetic Modeling and Experimental Pharmacokinetics in AnimalsHidetoshi Shimizu, Kosuke Yoshida, Tomohisa Nakada, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 5, 2017
Comparison of Methods for Estimating Unbound Intracellular-to-Medium Concentration Ratios in Rat and Human Hepatocytes Using StatinsTakashi Yoshikado, Kota Toshimoto, Tomohisa Nakada, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 23, 2026
Integrating B Cell Differentiation Model With Real-World Data Informs Determinants for Antibody-Secreting Cell Depletions in Systemic SclerosisTomohisa Nakada, Ryuta Saito, Sho Ishigaki, et al.
Pageof 2